To the full analysis
AptarGroup stock: growth
ATRAptarGroup reported $3.78B in revenue for fiscal 2025, up 5.4% on the prior year, up 5.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.6%
per year from 2006 to 2025, per share 4.9%
Earnings (Annual rate)
7.3%
per year from 2006 to 2025, per share 7.6%
Free cash flow (Annual rate)
6.8%
per year from 2006 to 2025, per share 7.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 5.2% | 5.0% | 4.6% |
| Revenue per share | 4.8% | 4.5% | 4.9% |
| Earnings | 12.9% | 7.0% | 7.3% |
| Earnings per share | 12.5% | 6.5% | 7.6% |
| Free cash flow | −1.2% | 5.6% | 6.8% |
| Free cash flow per share | −1.6% | 5.0% | 7.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.6B | $102.9M | $85.1M |
| 2007 | $1.89B | $141.74M | $134.32M |
| 2008 | $2.07B | $153.5M | $65.29M |
| 2009 | $1.84B | $124.62M | $134.56M |
| 2010 | $2.08B | $173.48M | $159.43M |
| 2011 | $2.34B | $183.68M | $81.35M |
| 2012 | $2.33B | $162.61M | $139.84M |
| 2013 | $2.52B | $171.99M | $133.87M |
| 2014 | $2.6B | $191.66M | $154.38M |
| 2015 | $2.32B | $199.35M | $174.44M |
| 2016 | $2.33B | $205.59M | $193.82M |
| 2017 | $2.47B | $220.03M | $168.11M |
| 2018 | $2.76B | $194.75M | $101.77M |
| 2019 | $2.86B | $242.2M | $267.38M |
| 2020 | $2.93B | $214.04M | $318.11M |
| 2021 | $3.23B | $244.1M | $55.51M |
| 2022 | $3.32B | $239.29M | $163M |
| 2023 | $3.49B | $284.49M | $256.84M |
| 2024 | $3.58B | $374.54M | $349.22M |
| 2025 | $3.78B | $392.79M | $299.58M |
Revenue by segment
How AptarGroup, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Pharma$1.7B46%
- Beauty$1.3B35%
- Other$730.3M19%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Pharma | $1.74B | 46% |
| Beauty | $1.31B | 34.7% |
| Other | $730.26M | 19.3% |
| Total revenue | $3.78B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Dec 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.